NR4A1 and breast carcinoma: In this study, we selected four 3,5-disubstituted CDIM compounds which exhibited the lowest KD values for binding NR4A1 (Figure 1) and investigated their activity as antagonists of NR4A1-regulated pro-oncogenic pathways/gene products in MDA-MB-231 and SKBR3 breast cancer cells.